Vimarsana
Biggest News Aggregation in the World

Page 44 - Eva Mathews News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Eva Mathews. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Eva Mathews Today - Breaking & Trending Today

GSK raises annual forecasts again on strong Arexvy launch - Vimarsana News

GSK raises annual forecasts again on strong Arexvy launch

Analysts expect GSK's RSV vaccine Arexvy to power future growth, stemming worries about the strength of its pipeline of drugs in development and costly U.S. litigation over discontinued heartburn drug Zantac. Arexvy, launched in the United States recently, is expected to garner full-year sales of between 900 million pounds to 1 billion pounds ($1.22 billion), GSK said. The London-listed drugmaker said it now expects a rise of 17% to 20% in annual adjusted earnings per share, excluding the effect

Source: aol.com
GSK raises annual sales, profit forecasts for second time - Vimarsana News

GSK raises annual sales, profit forecasts for second time

GSK raised its full-year profit and sales forecasts on Wednesday for the second time this year, betting on strong demand for its respiratory syncytial virus and shingles vaccines....

GSK raises annual forecasts powered by strong Arexvy launch - Vimarsana News

GSK raises annual forecasts powered by strong Arexvy launch

GSK on Wednesday raised its full-year profit and sales forecasts for a second time, after better-than-expected quarterly sales of its newly-launched respiratory syncytial virus (RSV) vaccine. GSK is betting on RSV vaccine Arexvy to be its next blockbuster medicine as it faces a combination of patent expiries and declining revenue from its current bestsellers by the end of this decade. Arexvy, launched in the United States recently, recorded third quarter sales of 709 million pounds ($862 million), trouncing analysts' expectations of 358 million pounds, according to a company-compiled co...

Source: yahoo.com
UK regulator approves Pfizer's hair loss drug - Vimarsana News

UK regulator approves Pfizer's hair loss drug

Britain's medicines regulator on Wednesday approved Pfizer Inc's drug to treat hair loss caused by an autoimmune disease. The drug, branded as Litfulo, has been approved by UK's Medicines and Healthcare products Regulatory Agency (MHRA) for people aged 12 years and older suffering from severe alopecia areata. It has already been approved for use in Europe and the United States.

Source: yahoo.com
UK regulator approves Pfizer's hair loss drug | WKZO | Everything Kalamazoo - Vimarsana News

UK regulator approves Pfizer's hair loss drug | WKZO | Everything Kalamazoo

(Reuters) - Britain's medicines regulator on Wednesday approved Pfizer Inc's drug to treat hair loss caused by an autoimmune disease. The drug, brande...

Source: wkzo.com